Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 5,201 Shares of Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider Solomon Moshkevich sold 5,201 shares of the business's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $165.87, for a total transaction of $862,689.87. Following the completion of the sale, the insider now directly owns 135,483 shares of the company's stock, valued at approximately $22,472,565.21. This trade represents a 3.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, January 22nd, Solomon Moshkevich sold 24,861 shares of Natera stock. The stock was sold at an average price of $164.97, for a total value of $4,101,319.17.
• On Monday, December 9th, Solomon Moshkevich sold 4,858 shares of Natera stock. The stock was sold at an average price of $166.59, for a total transaction of $809,294.22.

Natera Price Performance

Shares of NASDAQ:NTRA traded down $2.32 on Tuesday, hitting $174.24. The company had a trading volume of 1,123,762 shares, compared to its average volume of 1,398,269. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The company has a market cap of $23.00 billion, a PE ratio of -99.00 and a beta of 1.66. Natera, Inc. has a 52-week low of $66.68 and a 52-week high of $183.00. The business has a 50 day moving average of $167.14 and a 200 day moving average of $139.03.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm's quarterly revenue was up 63.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.95) EPS. As a group, equities analysts anticipate that Natera, Inc. will post -1.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on NTRA. JPMorgan Chase & Co. raised their price target on Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a report on Friday, December 13th. Sanford C. Bernstein raised their price objective on shares of Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a research report on Friday, January 10th. Morgan Stanley boosted their target price on Natera from $132.00 to $176.00 and gave the stock an "overweight" rating in a research report on Thursday, November 14th. Leerink Partners raised their price target on Natera from $140.00 to $150.00 and gave the company an "outperform" rating in a report on Thursday, October 17th. Finally, Piper Sandler upped their price objective on Natera from $150.00 to $200.00 and gave the stock an "overweight" rating in a report on Monday, November 18th. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $165.88.

Institutional Trading of Natera

Several hedge funds and other institutional investors have recently bought and sold shares of NTRA. Wellington Management Group LLP boosted its holdings in shares of Natera by 205.4% during the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company's stock worth $355,493,000 after purchasing an additional 1,883,481 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Natera by 3.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company's stock worth $315,194,000 after buying an additional 85,236 shares during the last quarter. Geode Capital Management LLC boosted its stake in Natera by 7.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company's stock worth $265,747,000 after buying an additional 143,825 shares during the last quarter. Maverick Capital Ltd. grew its holdings in Natera by 25.2% in the 3rd quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company's stock valued at $170,119,000 after buying an additional 269,706 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of Natera by 25.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,229,558 shares of the medical research company's stock valued at $156,092,000 after acquiring an additional 246,246 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.